BOR15001L7

Phase 2Small molecule

LLaboratoire Boreaderme Inc.

BOR15001L7 is one of 11 small molecule programs targeting Herpes Labialis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Herpes LabialisActive, not recruiting

Herpes LabialisPhase 2

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Herpes Labialis

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

2 2

Valtrex

GGlaxo Dba Glaxosmithkline

Zovirax

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glutamine

1 6

NB-001

NNobias Therapeutics, Inc.

Phase 3

3 7

Abreva

HHALEON

Phase 2

2 8

Squaric Acid Dibutyl Ester

SSquarex, LLC

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

BOR15001L7

LLaboratoire Boreaderme Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Herpes Labialis1 trial

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Unknown status·LLaboratoire Boreaderme Inc.·Phase 2·NCT03977792·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BOR15001L7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BOR15001L7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BOR15001L7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratoire Boreaderme Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLaboratoire Boreaderme Inc.

BOR15001L7

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Herpes Labialis1 trial

References

Drug Info

Quick Facts

Related News